Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.
A rare intestinal lymphoma subgroup with specific genetic changes may respond to approved immunotherapy drugs previously unavailable for this condition.
MEITL is an exceptionally rare and deadly intestinal T-cell lymphoma with no established effective treatments. This study identifies MMR deficiency via genomic MLH1/PMS2 loss in a subset of MEITL cases, opening a potential treatment avenue with pembrolizumab or other PD-1/PD-L1 inhibitors approved for MMR-deficient solid tumors.
What the study was
- Study design
- retrospective_cohort
- Population
- Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) patients
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Blood Cancer J
Why it surfaced
High-priority: identifies a novel molecular subgroup in a rare lymphoma with critical unmet need; MMR deficiency is a clinically actionable biomarker with FDA-approved therapies; published in Blood Cancer Journal (Nature Publishing Group); direct implications for rare disease trial design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.